Spur Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA for FLT201, Its Gene ...
FDA aligned on single-arm Phase 3 study to support potential accelerated and full approval On track to dose first patient in Phase 3 trial in second half of 2025 LONDON, Feb. 03, 2025 (GLOBE NEWSWIRE) ...